Determination of Ciprofloxacin in Human Plasma and Urine by Precolumn Derivatization High Performance Liquid Chromatography with Fluorescence Detection

A sensitive, simple and selective high‐performance liquid chromatographic (HPLC) method was developed for the determination of ciprofloxacin in biological fluids. The method is based on the reaction between the drug and 4‐chloro‐7‐nitrobenzofurazan (NBD‐Cl) in borate buffer of pH 9.0 to yield a highly fluorescent derivative that is measured at 535 nm after excitation at 464 nm. The calibration curves were linear over the concentration ranges of 25–3000 and 50–3000 ng·mL^?1 for plasma and urine, respectively. The mean recovery of ciprofloxacin from plasma and urine was 98.37% and 98.40%, respectively. The method was found to be sensitive, precise, accurate, and reproducible. All of the validation parameters were within the acceptance range.     

Determination of fluvoxamine in rat plasma by HPLC with pre-column derivatization and fluorescence detection using 4-fluoro-7-nitro-2,1,3-benzoxadiazole

A sensitive, simple and reliable method using high-performance liquid chromatographic (HPLC) assay of fluvoxamine (FLU), a selective serotonin reuptake inhibitor (SSRI), in rat plasma after pre-column derivatization with 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) was developed in this study. Extracted plasma samples were mixed with NBD-F at 60 degrees C for 5 min and injected into HPLC. Retention times of FLU and an internal standard (propafenone) derivative were 15.5 and 13.5 min, respectively. The calibration curve was linear over the range 0.015-1.5 microg/mL (r2 = 0.9985) and the lower limits of detection and quantification of FLU were 0.008 and 0.015 microg/mL, respectively, in 100 microL of plasma. The derivative sample was stable at 4 degrees C for 1 day. The coefficients of variation for intra-day and inter-day assay of FLU were less than 8.3 and 9.6%, respectively. Other SSRIs and centrally acting drugs did not interfere with the peak of the FLU derivative. The method was applied for analysis of the plasma samples from rats treated with FLU. These results indicate that the method presented is useful to determine the FLU levels in rat plasma of volumes as small as 100 microL and can be applied to pharmacokinetic studies.     

Determination of amino acid neurotransmitters in rat hippocampi by HPLC‐UV using NBD‐F as a derivative

A simple, rapid and accurate high‐performance liquid chromatography method with ultraviolet–visible detection was developed for the determination of five amino acid neurotransmitters – aspartate, glutamic acid, glycine, taurine and γ‐aminobutyric acid – in rat hippocampi with pre‐column derivatization with 4‐fluoro‐7‐nitrobenzofurazan. Several conditions which influenced derivatization and separation, such as pH, temperature, acetonitrile percentage mobile phase and flow rate, were optimized to obtain a suitable protocol for amino acids quantification in samples. The separation of the five neurotransmitter derivatives was performed on a C₁₈ column using a mobile phase consisting of phosphate buffer (0.02 mol/L, pH 6.0)–acetonitrile (84:16, v/v) at a flow rate of 1.0 mL/min with the column temperature at 30°C. The detection wavelength was 472 nm. Without gradient elution, the five neurotransmitter derivatives were completely separated within 15 min. The linear relation was good in the range from 0.50 to 500 µmol/L, and the correlation coefficients were ≥0.999. Intra‐day precision was between 1.8 and 3.2%, and inter‐day precision was between 2.4 and 4.7%. The limits of detection (signal‐to‐noise ratio 3) were from 0.02 to 0.15 µmol/L. The established method was used to determine amino acid neurotransmitters in rat hippocampi with satisfactory recoveries varying from 94.9 to 105.2%. Copyright © 2013 John Wiley & Sons, Ltd.     

Sensitive determination of 4-(4-chlorophenyl)-4-hydroxypiperidine, a metabolite of haloperidol, in a rat biological sample by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole

4-(4-Chlorophenyl)-4-hydroxypiperidine (CPHP), one of the metabolites of haloperidol, is considered to exhibit brain toxicity. CPHP concentrations in plasma and tissue homogenates (each 200 microL) from rats were analyzed by HPLC fluorescence detection after pre-column derivatization with 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F). After basic extraction of the samples with benzene, the derivatization with NBD-F was conducted in borate buffer (pH 8.0) at 60 degrees C for 3 min. Mexiletine was carried through the procedure as an internal standard. The regression equation for CPHP showed a good linearity in the range of 0.03-1 microg/mL with a detection limit of 0.008 microg/mL. The coefficient of variation was less than 11.6%. Plasma concentration-time courses of CPHP after intraperitoneal or per oral administration of CPHP, haloperidol or reduced haloperidol were examined, and the pharmacokinetic parameters were estimated. Additionally, CPHP levels in various tissues at 8 h after intraperitoneal administration of these compounds were compared. The method was simple and sensitive, useful for determination of CPHP in rat biological samples using as little as 200 microL of sample volume and could be applied for pharmacokinetic study.     

Fluorimetric Determination of Gentamicin in Dosage Forms and Biological Fluids Through Derivatization with 4-Chloro-7-Nitrobenzo-2-Oxa-1,3-Diazole (NBD-Cl)

 A highly sensitive fluorimetric method has been developed for the determination of gentamicin. The method is based on its coupling with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) in 50% (v/v) methanolic phosphate buffer (pH 7.2) to give an intensely fluorescent product having excitation and emission wavelengths at 465 nm and 530 nm, respectively. The experimental parameters were carefully studied and incorporated into the procedure. The fluorescence-concentration plot is rectilinear over the range 0.56–2.8 μg/mL (r = 0.999) with minimum detectability (S/N = 2) of 0.11 μg/mL (1.6 × 10⁻⁷ mol/L). The method was applied successfully to the determination of the drug in pharmaceutical dosage forms and the percentage recoveries were satisfactorily accurate and precise. The method was further applied to spiked human plasma samples, the percentage recovery was 97.9 ± 3.4. The interference encountered from endogenous amino acids could be eliminated through selective complexation with freshly prepared copper (II) hydroxide. A proposal of the reaction pathway is presented. The method can measure the intact drug, and can be used in presence of possible interference. Received April 18, 2001; accepted April 10, 2002     

Sensitive Spectrofluorimetric Method of Analysis for Gabapentin in Pure and Pharmaceutical Preparations

Highly sensitive spectrofluorimetric method was developed and validated for the determination of gabapentin in pure and pharmaceutical preparations. The method was based on nucleophilic substitution reaction of gabapentin with 4‐fluoro‐7‐nitrobenzofurazan (NBD‐F) in an alkaline medium (pH 9.5) to form a highly fluorescent derivative that was measured at 521 nm after excitation at 458 nm. The factors affecting the reaction was carefully studied and optimized. The method was successfully validated for linearity, limit of detection, limit of quantification, accuracy, precision, robustness and specificity. Under the optimized conditions, linear relationship with good correlation coefficient (0.9998) was found between the relative fluorescence intensity and gabapentin concentration in the range of 10–100 ng·mL^?1. The limit of detection and limit of quantification were 0.43 and 1.30 ng·mL^?1, respectively. The proposed method was successfully applied to the determination of gabapentin in its pharmaceutical capsules. The results obtained by the proposed method were comparable with those obtained by the official method. Statistical comparison by t‐ and F‐ tests revealed that there was no significant difference between the results of the two methods with respect to mean values and standard deviations at the 95% confidence level.     

Spectrofluorimetric and Spectrophotometric Determination of Oxamniquine in Pharmaceuticals and Biological Fluids via Derivatization with 4‐Chloro‐7‐Nitrobenzo‐2‐oxa‐1,3‐Diazole (NBD‐Cl)

Spectrophotometric and spectrofluorimetric methods were developed for the determination of oxamniquine (OXM). Both methods are based on coupling with 4‐chloro‐7‐nitrobenzo‐2‐oxa‐1,3‐diazole (NBD‐Cl) in borate buffer of pH 7.6, and the reaction product was measured at 400 nm (Method I). The same product was measured by spectrofluorimetry at 480 nm upon excitation at 400 nm (Method II). The absorbance and the fluorescence intensity were enhanced by addition of sodium dodecyl sulphate (SDS). The absorbance‐concentration plot is rectilinear over the range of 5–25 μg/mL with an LOD of 0.31 μg/mL. The fluorescence‐concentration plot is linear over the range of 0.2–1.2 μg/mL with an LOD of 0.03 μg/mL. Both methods were applied to the analysis of capsules, and the results were in good agreement with those obtained using the official method. The method was applied to spiked human plasma; the mean % recovery (n = 5) is 101.05 ± 1.65. A proposal of the reaction pathway is presented.     

柱前衍生-反相高效液相色谱法测定氨基酸

向氨基酸溶液中加入对甲氧基苯磺酰氯(MOBS-Cl)试剂,在55℃水浴中加热35min使氨基酸衍生化,所得含有氨基酸衍生物的溶液用于反相高效液相色谱分析。选用ODS C_(18)柱(4.6mm×150mm,5.0μm)为固定相,以不同体积比的15mmol·L~(-1)磷酸二氢钠溶液和乙腈为流动相进行梯度淋洗,以235nm作为检测波长,提出了测定氨基酸的柱前衍生-反相高效液相色谱法。17种氨基酸衍生物的峰面积与其浓度均在0.01～5.0mmol·L~(-1)范围内呈线性关系,检出限(3S/N)在0.0010～0.0050mmol·L~(-1)之间。取5.0,25.0,50.0g·L~(-1)氨基酸标准溶液从衍生化操作开始分别重复测定5次,根据所测得峰面积值计算其相对标准偏差均小于5.0%。     

柱前衍生化/毛细管电泳法测定阿伦膦酸钠

建立了一种以对甲氧基苯磺酰氯为紫外衍生试剂柱前衍生,毛细管电泳法测定阿伦膦酸钠的分析方法。阿伦膦酸钠与对甲氧基苯磺酰氯的衍生条件为:在20 mmol/L的硼酸盐缓冲溶液(pH 11.5)中,摩尔比为1:10的阿伦膦酸钠与对甲氧基苯磺酰氯在50℃下反应10 min。将衍生产物在毛细管电泳上进行分离,使用pH 9.3 20 mmoL/L的硼酸盐缓冲溶液为分离缓冲体系,柱温25℃,分离电压20 kV,在0.5 psi压力下进样5 s,以二级管阵列(DAD)检测器在233 nm处进行检测。测得阿伦膦酸钠的线性范围为1.0~400μg/mL,检出限为0.5~1.0μg/mL。方法用于药物制剂阿伦膦酸钠片和尿液介质中阿伦膦酸钠的测定,结果满意。     

Simultaneous liquid chromatographic assay of amantadine and its four related compounds in phosphate-buffered saline using 4-fluoro-7-nitro-2,1,3-benzoxadiazole as a fluorescent derivatization reagent

Simultaneous HPLC assay of 1-adamantanamine hydrochloride (amantadine) and its four related compounds [2-adamantanamine hydrochloride (2-ADA), 1-adamantanmethylamine (ADAMA), 1-(1-adamantyl)ethylamine hydrochloride (rimantadine) and 3,5-dimethyl-1-adamantanamine hydrochloride (memantine)] in phosphate-buffered saline (pH 7.4) after pre-column derivatization with 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) was developed. Phosphate-buffered saline samples were mixed with borate buffer and NBD-F solution in acetonitrile at 60 degrees C for 5 min and injected into HPLC. Five derivatives were well separated from each other. The lower limits of detection of amantadine, 2-ADA, ADAMA, rimantadine and memantine were 0.008, 0.001, 0.0008, 0.0015 and 0.01 microg/mL, respectively. The coefficients of variation for intra- and inter-day assay were less than 6.4 and 8.2%, respectively. The method presented was applied to a binding study of these compounds to human alpha(1)-acid glycoprotein. While affinity constants and capacities for ADAMA, rimantadine and memantine were calculated by means of Scatchard plots, those for the others were not determined. ADAMA, rimantadine and memantine were bound with different affinities and capacities. These results indicate that NBD-F is a good candidate as a fluorescent reagent to simultaneously determine amantadine and its four related compounds by HPLC after pre-column derivatization. Our method can be applied to binding studies for protein.     

Synthesis of 4-aryloxy-7-nitrobenzofurazan derivatives from 4-chloro-7-nitrobenzofurazan and various phenoxide anions (including pharmaceuticals) in the presence of crown ethers

4-Chloro-7-nitrobenzofurazan reacts by nucleophilic substitution with phenoxide anions derived from estriol (2c), ethynylestradiol (2d), phenol (3e), guaiacol (3f), 2,6-dimethoxyphenol (3g), eugenol (3h), isoeugenol (3i), the cytostatic Etoposide (4), and Reichardt’s betaine (5) in the presence of crown ethers affording the corresponding 4-aryloxy-7-nitrobenzofurazan derivatives 6c, 6d, 7e-7i, 8, and 9. The structure of these compounds was confirmed by NMR spectra. Hydrophobicity/hydrophilicity parameters were investigated by reverse phase thin-layer chromatography.     

柱前衍生化高效液相色谱测定血清中红霉胺

建立了人血清中地红霉素活性代谢物红霉胺的高效液相色谱荧光检测方法.用甲基叔丁基醚萃取血清中红霉胺,用NBD-Cl衍生化后于反相C18柱上进行分离测定.流动相为V(0.01 mol/L 磷酸盐缓冲液,pH 6.0)∶ V(乙腈)=80∶ 20混合液,流速为1.0 mL/min,地洛他定为内标,标准曲线的线性范围为0.010～1.245 mg/L,日内和日间相对标准偏差均小于9%.最低定量限为10 μg/L.应用本方法对受试者给予地红霉素后血清中的红霉胺浓度进行了测定.     

Fluorescent detection of peptides and amino acids for capillary electrophoresis via on-line derivatization with 4-fluoro-7-nitro-2,1,3-benzoxadiazole

An in-capillary derivatization of amino acids and peptides with 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) was developed for their subsequent capillary electrophoretic analysis with laser-induced fluorescence detection (λ _ex=488 nm). The in-capillary derivatization was achieved in zone-passing mode by introducing successive plugs of sample and NBD-F into a fused silica capillary previously equilibrated with an alkaline borate buffer. To prevent NBD-F hydrolysis and to achieve a reliable derivatization, NBD-F was prepared daily in absolute ethanol and a plug of absolute ethanol was introduced between the sample and NBD-F reagent plugs. Various parameters influencing the derivatization efficiency were investigated and the optimum conditions were as follows: background electrolyte (BGE), 20 mM borate buffer (pH 8.8); introduction time, 4 s for sample and 2 s for NBD-F; molar ratio of NBD-F/sample, above 215; temperature, 45 °C for amino acids and 35 °C for peptides; applied voltage, +15 kV. The validation of the in-capillary derivatization method under optimal conditions showed a good linearity between the heights of the derivative peaks and the concentrations of the amino acids. The intra-day relative standard deviations of the migration times and the peak heights were less than 1.3% and 4.6%, respectively. The efficient derivatization and separation of a mixture of valine, alanine, glutamic acid and aspartic acid were achieved using this technique. Peptides such as buccaline and β-protein fragment 1–42 could also be derivatized using the developed in-capillary derivatization procedure. In‑capillary derivatization and separation of amino acids with different concentrations. From the top to bottom the concentrations are 1.11×10⁻⁵ M, 5.55×10⁻⁶ M, 2.78×10⁻⁶ M, 6.95×10⁻⁷ M. for valine; 1.26×10⁻⁵ M, 6.30×10⁻⁶ M, 3.15×10⁻⁶ M, 7.88×10⁻⁷ M for alanine; 3.78×10⁻⁵ M, 1.89×10⁻⁵ M, 9.45×10⁻⁶ M, 2.36×10⁻⁶ M for glutamic acid;, 4.27×10⁻⁵ M, 2.14×10⁻⁵ M, 1.07×10⁻⁵ M, 2.68×10⁻⁶ M for aspartic acid. Experiment conditions: injection order: 4s for sample, 1s for absolute ethanol, and then 2s for 5.24×10⁻² M NBD‑F; BGE: 20 mM borate pH 8.77; Applied voltage: 15 kV.     

High Performance Liquid Chromatography for the Determination of Metoclopramide in Pharmaceutical Preparations Using Pre‐column Derivatization with Fluorescamine

A simple, rapid and sensitive high performance liquid chromatography (HPLC) method was developed for the determination of metoclopramide in pharmaceutical preparation. The method is based on the derivatization of metoclopramide with fluorescamine. The separation was achieved on a C₁₈ column using methanol‐water (70:30, V/V) mobile phase. Fluorescence detector was used at the excitation and emission of 403 and 485 nm, respectively. The method was validated for linearity, limit of detection, limit of quantification, precision, accuracy, recovery, robustness and system suitability. The assay was linear over the concentration range of 100–2000 ng/mL. The mean recovery was 100.37%. The proposed method was successfully applied to the assay of metoclopramide in tablet preparation. The preparation was also analyzed with an official method and statistical comparison by t‐ and F‐tests revealed that there was no significant difference between the results of the two methods with respect to mean values and standard deviations at the 95% confidence level.     

固相萃取柱上衍生气相色谱-质谱法测定水中烷基酚

以烷基酚(APs)主要降解产物辛基酚(4-t-OP)、壬基酚(4-n-NP)为研究对象,建立了固相萃取(SPE)柱上衍生化、气相色谱-质谱(GC-MS)法测定水中APs的分析方法。以C18柱为固相萃取柱、N,O-(三甲基硅)三氟乙酰胺(BSTFA)为硅烷化试剂,设计五因素四水平正交实验L16(45),对衍生化影响因素、衍生化溶剂、衍生化时间以及SPE主要影响因素pH值、盐度和洗脱剂进行优化;在优化条件下,方法的回收率(高于80%)和重现性(RSD低于10%)结果令人满意,4-t-OP和4-n-NP的仪器检出限分别为3.35ng/L和6.38ng/L。采用建立的方法,回收率略高于传统的SPE萃取衍生法,具有有机溶剂用量少,方法简单快速、灵敏度高的特点,适用于河水和海水中痕量烷基酚的快速测定。     

Stability Indicating HPTLC and LC Determination of Dasatinib in Pharmaceutical Dosage Form

Two sensitive and reproducible methods are described for the quantitative determination of dasatinib in the presence of its degradation products. The first method was based on high performance thin layer chromatography (HPTLC) followed by densitometric measurements of their spots at 280 nm. The separation was on HPTLC aluminium sheets of silica gel 60 F₂₅₄ using toluene:chloroform (7.0:3.0, v/v). This system was found to give compact spots for dasatinib after development (R _F value of 0.23 ± 0.02). The second method was based on high performance liquid chromatography (HPLC) of the drug from its degradation products on reversed phase, PerfectSil column [C₁₈ (5 μm, 25 cm × 4.6 mm, i.d.)] at ambient temperature using mobile phase consisting of methanol:20 mM ammonium acetate with acetic acid (45:55, v/v) pH 3.0 and retention time (t _R = 8.23 ± 0.02 min). Both separation methods were validated as per the ICH guidelines. No chromatographic interference from the tablet excipients was found. Dasatinib was subjected to acid–alkali hydrolysis, oxidation, dry heat, wet heat and photo-degradation. The drug was susceptible to acid–alkali hydrolysis and oxidation. The drug was found to be stable in neutral, wet heat, dry heat and photo-degradation conditions. As the proposed analytical methods could effectively separate the drug from its degradation products, they can be employed as stability indicating.     

柱前衍生高效液相色谱法测定血清中克拉霉素的含量

建立了2，4-二硝基苯肼柱前衍生反相高效液相色谱紫外检测法测定血清中克拉霉素的含量，将在碱性条件下甲基叔丁基醚的血清萃取物，与2，4-二硝基苯肼在55％酸性条件下反应30min，然后用乙腈-0．05mol/LpH7．2磷酸盐缓冲液（48：52）在Alltima C18色谱柱上进行分离，在340nm检测衍生物。方法的线性范围为0．05～3．2mg／L（r=0．9993）；检出限为30μg/L，绝对回收率大于89％，相对标准差小于10％。本方法已用于克拉霉素在健康受试者中的药代动力学研究。     

Stability-Indicating LC Determination of Nitazoxanide in Bulk Drug and in Pharmaceutical Dosage Form

A novel stability-indicating high-performance liquid chromatographic assay method was developed and validated for quantitative determination of nitazoxanide in bulk drugs and in pharmaceutical dosage form in the presence of degradation products generated from forced decomposition studies. An isocratic, reversed phase LC method was developed to separate the drug from the degradation products, using an Ace5- C18 (250 mm × 4.6 mm, 5 μm) column, and 50 mM ammonium acetate (pH 5.5 by acetic acid) and acetonitrile (55:45 v/v) as a mobile phase. The detection was carried out at a wavelength of 240 nm. The nitazoxanide was subjected to stress conditions of hydrolysis (acid, base), oxidation, photolysis and thermal degradation. Degradation was observed for nitazoxanide in base, acid and in 30% H₂O₂ conditions. The drug was found to be stable in the other stress conditions attempted. The degradation products were well resolved from the main peak. The percentage recovery of nitazoxanide was from (100.55 to 101.25%) in the pharmaceutical dosage form. The developed method was validated with respect to linearity, accuracy (recovery), precision, system suitability, specificity and robustness. The forced degradation studies prove the stability indicating power of the method.     

柱后衍生-高效液相色谱法测定水中呋喃丹和甲萘威

提出了测定水中呋喃丹和甲萘威的柱后衍生-高效液相色谱法。水样经盐酸酸化至pH 3后,用0.45μm水性滤膜过滤,取200μL水样直接进样,用Waters Carbamate Analysis分析柱(3.9 mm×150 mm,5μm)和以甲醇-乙腈-水(1+1+3)混合液作为流动相进行分离。分离后用2 g·L-1氢氧化钠溶液进行水解,用每升中含邻苯二甲醛0.1 g、十水硼酸钠19.1 g及2-巯基乙醇0.5 mL的溶液进行衍生化,用荧光检测器在激发波长(eλx)为339 nm,发射波长(eλm)为445 nm处检测。方法检出限(3S/N)均为4×10-4mg·L-1。应用此方法测定了水厂出厂水和河水中呋喃丹和甲萘威,并用标准加入法做回收试验,测得其平均回收率依次为93.0%~98.0%之间和93.0%~99.4%之间,相对标准偏差(n=6)小于0.50%。     

Quantitative Analysis of Sertraline in Human Serum by LC with Fluorescence Detection After Pre-Column Derivatization with 4-Chloro-7-nitrobenzofurazan

An accurate and sensitive reversed-phase high-performance liquid chromatographic method for analysis of sertraline in human serum, using 4-chloro-7-nitrobenzofurazan as pre-column derivatization agent, is described. The drug and an internal standard (azithromycin) were extracted from serum by use of a mixture of diethyl ether and chloroform, and subjected to pre-column derivatization with the reagent. Analysis of the resulting derivatives was performed on a 250 mm × 4.0 mm cyano column with 63:37 (v/v) methanol–sodium phosphate buffer (0.05 M, pH 3.7) containing 2 mL L^?1 triethylamine as mobile phase. Detector response was monitored at excitation and emission wavelengths of 470 and 537 nm, respectively. The calibration plot was linear over the concentration range 2–640 ng mL^?1. The lower limits of detection and quantification were 0.5 and 2 ng mL^?1, respectively. The method was validated for specificity, sensitivity, linearity, precision, accuracy, and stability and shown to be accurate (intra-day and inter-day accuracy from 0.3 to 4.2%) and precise (intra-day and inter-day precision from 2.4 to 15.5%). The drug was detected at concentrations as low as 2 ng mL^?1 in 0.5 mL serum and the method described can be easily applied to human single-dose pharmacokinetic studies of sertraline.